Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: AIDS. 2010 Jun 1;24(9):1377–1380. doi: 10.1097/QAD.0b013e3283396024

Figure 1. Changes in flow-mediated dilation (FMD), interferon-gamma-induced protein (IP-10), and soluble vascular cell adhesion molecule-1 (sVCAM-1) with use of pentoxifylline (PTX) in HIV-infected subjects not requiring cART.

Figure 1

(A) FMD increased nearly uniformly from baseline in 7 of 8 subjects who completed the 8 week trial. (B) Changes in overall FMD levels as shown as boxplots (medians represented as horizontal lines within the boxes; bottoms and tops of boxes represent 25th and 75th percentiles, respectively; lower and upper horizontal lines outside of boxes represent minimum and maximum levels, respectively). Median absolute FMD significantly increased from baseline/week 0 (N=9; 2.1%) to study weeks 4 (N=8; 5.5%; p=0.04) and 8 (N=7; 8.2%; p=0.02). (C) IP-10 levels decreased significantly (P<0.05) over 8 weeks in the 7 subjects who completed the trial. (D) sVCAM-1 levels also decreased significantly (P<0.05) over 8 weeks in the 7 subjects who completed the trial.